SCHEMBL3174433

SCHEMBL3174433

Cc1ccc(-n2nc(C(C)(C)CF)cc2NC(=O)N(OS(C)(=O)=O)c2cnc(N3CCN(C(=O)c4c(F)cccc4F)CC3)c(C)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.38
MAPK13 O15264 7/20 0.38
MAPK12 P53778 5/20 0.38
MAPK11 Q15759 4/20 0.38
PTK2B Q14289 2/20 0.35
CDK8 P49336 3/20 0.34
DDR2 Q16832 2/20 0.34
HCK P08631 2/20 0.33
CIT O14578 1/20 0.33
MUSK O15146 1/20 0.33
MAP3K7 O43318 1/20 0.33
RIPK2 O43353 1/20 0.33
STK10 O94804 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.33
ABL1 P00519 1/20 0.33
EGFR P00533 1/20 0.33
TNF P01375 1/20 0.33
RAF1 P04049 1/20 0.33
NTRK1 P04629 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3389381 0.86 KCNJ6 (0.40) MAPK14MAPK13MAPK12MAPK11HCK
SCHEMBL3174424 0.85 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL3388827 0.84 MAPK14 (0.38) MAPK14MAPK13MAPK12MAPK11HCK
SCHEMBL3174613 0.83 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL3392522 0.83 MAPK14 (0.36) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL3180417 0.78 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL4481650 0.77 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL3180282 0.77 MAPK14 (0.55) MAPK14MAPK13MAPK12MAPK11PTK2B
SCHEMBL3388897 0.76 KCNJ6 (0.41) MAPK14MAPK13MAPK12MAPK11CDK8
SCHEMBL3392537 0.76 MAPK14 (0.37) MAPK14MAPK13MAPK12MAPK11PTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1943243-B1 KINASE INHIBITORS LILLY CO ELI (US) 2010-12-29 EP disclosed
US-7652015-B2 Suppression cytokines , tumor necrosis factor ELI LILLY AND COMPANY (US) 2010-01-26 US disclosed
US-20080269244-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269244-A1 Kinase Inhibitors MAP3K1, MAP3K20, MAP3K19 MAPK14 58/4885MAPK13 60/4885MAPK12 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.